The aim of this study was to determine the mechanism of tricuspid regurgitation (TR) progression in pulmonary arterial hypertension (PAH) and its effect on survival.
Introduction
Functional tricuspid regurgitation (TR), often secondary to pulmonary hypertension (PH), leads to right ventricular (RV) remodelling, tricuspid annular (TA) dilatation, papillary muscles displacement, and tricuspid valve (TV) leaflets tethering. 1 TR has been associated with heart failure, reduced functional capacity, and mortality. 2 -5 In patients with mitral valve disease secondary to rheumatic or ischaemic aetiology, atrial fibrillation (AF), baseline TR, and a large left atrium have been associated with TR progression. 6 -10 Recently, pulmonary artery systolic pressure (PASP) increase and permanent AF were identified as the dominant risk factors for TR progression in patients with low prevalence of rheumatic heart disease and preserved left ventricular function. 5 Pulmonary arterial hypertension (PAH) is defined as mean pulmonary artery pressure .25 mmHg associated with normal left atrial pressure and increased pulmonary vascular resistance. 11 The estimated prevalence of PAH ranges between 7 and 26 cases per 1 million adults. 12 PAH is often associated with severe PH and RV remodelling, which may lead to progressive RV failure and death. 13 Moderate or severe TR has been reported in 60% of patients with severe symptomatic idiopathic PAH, and its presence is associated with decreased exercise capacity and right heart failure. 2 There currently are limited data regarding TR progression and its impact on RV remodelling in PAH. The aims of this study were (1) to determine the factors associated with TR progression and regression in PAH, (2) to study RV remodelling associated with changes in TR severity, and (3) to determine the association of changes in TR severity with survival in PAH patients.
Methods Patients
The PAH registry at the University of Chicago Medical Center has been previously described. 14 Using this PAH registry, we identified 560 adult patients with Group 1 PAH according to the updated classification of PH. 11 Of these patients, 553 had clinically indicated transthoracic echocardiograms performed between February 1999 and August 2014. Using our combined PAH registry and digital echocardiographic database, we defined a prevalent cohort consisting of three groups of patients:
(1) TR regression group: All patients with serial echocardiograms who had moderate or severe TR on Echo 1 (defined as the last echocardiogram showing maximal degree of TR) and trivial or mild TR on Echo 2 (defined as the first echocardiogram with no more than mild TR). (2) Stable TR group: All patients with serial echocardiograms showing no more than mild TR, with a time interval of at least 1 year between echocardiograms and showing PASP of at least 50 mmHg on the last echocardiogram (Echo 2). The last criterion was used in order to avoid preselecting patients with relatively mild or transient PAH. (3) TR progression group: All patients with serial echocardiograms who had trivial or mild TR on Echo 1 (defined as the last echocardiogram with no more than mild TR) and moderate or severe TR on Echo 2 (defined as the first echocardiogram showing the maximal degree of TR). Only patients with persistent TR (having at least moderate TR on the last available echocardiograms) were included.
None of the patients had undergone TV surgery. We excluded one patient who had lung transplantation prior to Echo 2. Relevant clinical data were obtained from the PAH registry and electronic medical records. Haemodynamic data were obtained from the first right heart catheterization performed in each patient. Vital status of all patients was determined at 3 years after Echo 2. The study protocol was approved by the Institutional Review Board to allow use of data from the PH Connection registry. 14 
Echocardiography
A complete transthoracic echocardiographic study was performed using standard views and techniques. Digitally recorded studies of all patients were reviewed and analysed. TR severity was determined based on colour-flow Doppler imaging, TV leaflets anatomy and hepatic venous flow pattern, using the parasternal RV inflow, parasternal short axis, apical four-chamber, and the subcostal views. 15 Mild TR was defined as a small central jet, moderate TR as an intermediate jet, and severe TR as a large jet, or in the presence of leaflet malcoaptation (a visible gap between leaflets) or systolic flow reversal in the hepatic veins. 15 PASP was estimated from the TR jet using the view showing maximal jet velocity, and the right atrial pressure (RAP) was estimated from the inferior vena cava diameter and inspiratory collapse. 16 
RV and TV echocardiographic measurements
All right heart measurements were performed in the apical fourchamber or RV-focussed views. RV basal and mid diameters, length, and area were measured at end-diastole and end-systole, and fractional area change calculated [(diastolic area -systolic area)/diastolic area]. 16 RV basal to mid ratio and sphericity index (mid-diameter×length/basal diameter) were calculated in systole. 17 TA diameter was measured at end-diastole and end-systole, and TV tenting height and area were measured at maximal TV closure (Figures 1  and 2) . 18 TV leaflets' length (septal + opposing leaflets) was measured in diastole. 17 We defined TV coverage index as TV leaflets length/TV tenting area (1/cm).
Statistical analysis
Continuous variables are presented as mean + SD, and categorical variables as numbers and percentages. Baseline characteristics of the groups were compared using analysis of variance (ANOVA) for continuous variables and by the x 2 statistic for discrete variables. When continuous data were abnormally distributed, groups were compared with the nonparametric one-way ANOVA (Kruskal -Wallis test). Univariate comparisons were performed using tests for paired data, including the paired t-test for normally distributed continuous variables, the Wilcoxon matched pairs signed rank test for non-normally distributed continuous variables, and the x 2 test for categorical variables.
Intra-and interobserver reproducibility were evaluated in 20 randomly selected patients with the interclass correlation coefficient (ICC), by fitting a two-way random effects model. The intraobserver variability of RV measurements by ICC was between 0.94 and 0.98, and the interobserver variability varied from 0.77 to 0.97. Intra-and interobserver variability were lowest when re-measuring systolic RV basal diameter and highest with systolic RV length.
Multiple logistic regression models were estimated and used to calculate odds ratios (ORs) and corresponding 95% confidence intervals (CIs) for potential risk factors associated with TR progression. Covariates that could influence the risk of TR progression were included if found significant at the P , 0.05 level (Wald's test). Because of the small sample size, we sought a final parsimonious model that included only those variables that were independently associated with progression of TR in a stepwise-backward elimination procedure.
The impact of TR progression on subsequent mortality was evaluated starting at Echo 2. Survival curves were constructed using the KaplanMeier method, and comparisons were made using the log-rank test.
Stepwise Cox proportional hazards models with backward selection were used to calculate hazard ratios (HRs) and 95% CI for TR progression and other risk variables.
Thresholds for continuous variables were based on the values associated with the highest average of sensitivity and specificity on receiveroperating characteristic curve analysis for the event of interest. Possible nonlinearity in the relationships was tested for by using fractional polynomials. Differences were considered statistically significant at the twosided P , 0.05 level. Statistical analyses were performed using STATA Version 13.1 (College Station, TX).
Results
Moderate or severe TR was present in at least one echocardiogram in 239/553 (43%) of the patients with PAH, whereas severe TR in 116 patients (21%). Overall, 88 patients with serial echocardiograms who met the selection criteria for the three subgroups were included in our study, and 66% were in Functional Class 3 or 4. There were 17 patients in the TR regression group [6 with severe TR at baseline ( Figure 1 ) and 11 with moderate TR], 36 patients had stable TR, and 35 patients had TR progression [16 to severe ( Figure 2 ) and 19 to moderate TR]. The time interval between Echoes 1 and 2 was 3.9 + 2.5 years in the TR regression group, 6.0 + 2.6 years in the stable group, and 3.5 + 2.6 years in the TR progression group.
Patient characteristics and haemodynamic data are summarized in Table 1 . Most patients were women. PAH was idiopathic in 38 patients (hereditary in 3 of them), and associated with collagen vascular disease in 28, liver disease in 13, anorexigens in 4, human immunodeficiency virus in 2, and sickle cell disease in 2. There was a trend for more patients with idiopathic PAH in the TR regression and the stable groups, when compared with the TR progression group. Patients in the TR progression group were less likely to receive PAH-specific therapy. Combination therapy was used in 44 patients for an average duration of 3.7 + 2.9 years [14/35 (40%) in the TR progression group and 30/54 (56%) in the stable/ regression group, P ¼ 0.2]. AF was rare and not significantly different between groups. Only one patient (in the TR progression group) had permanent AF. Patients in the TR regression group had a higher pulmonary vascular resistance and lower cardiac index, reflecting baseline PAH severity.
TR progression and RV remodelling
Left ventricular size decreased with TR progression and increased with TR regression, which was also associated with increased left atrial size (Supplementary data online, Table S1 ). RV and right atrial size increased with TR progression and decreased with regression (Supplementary data online, Table S2 and Figure 3 ). There was no change in RV fractional area change. Changes in RV size were most prominent at the mid-ventricular level, with minimal change in RV length. RV sphericity increased with TR progression and decreased with TR regression.
TV anatomy and TR progression
TR was functional in all patients. Only one patient (in the TR progression group) had malcoaptation of the TV leaflets. There was no difference in baseline systolic (P ¼ 0.99) or diastolic (P ¼ 0.7) TA diameter between the stable and the TR progression groups. TA diameter, tenting height, and tenting area significantly increased with TR progression and decreased with TR regression but remained unchanged in patients with stable TR (Supplementary data online, Table S3 and Figure 4) . TV leaflet length increased insignificantly with TR progression, but significantly decreased with TR regression. As a result, TV coverage (leaflet length/tenting area) significantly decreased with TR progression and significantly increased with TR regression, but there was no change in the stable group.
Factors associated with TR progression
None of the baseline parameters, including PAH aetiology, drug therapy, baseline echocardiographic PASP, and baseline anatomic parameters such as TA diameter, tenting height and area, and RV size and geometry predicted TR progression. Baseline PASP was similar between the TR progression and stable TR groups (P ¼ 0.8). Over time, PASP decreased in the TR regression group, whereas it increased in the TR progression group, more than it increased in the stable TR group (Supplementary data online, Table S1 and Figure 5 ). The independent parameter changes associated with TR progression were PASP increase, decreased TV coverage, and increased RV diastolic area ( Table 2) .
Effect of TR progression on all-cause mortality
TR progression predicted all-cause mortality after Echo 2 ( Figure 6 ). Almost all patients (88%) in the TR progression group died within 3 years, when compared with 39% of the patients with stable TR and 22% with TR regression. Independent predictors of all-cause mortality were RAP increase from Echo 1 to Echo 2 and PASP and mid RV diastolic diameter index at Echo 2 ( Table 3) . Parenteral prostaglandin therapy independently predicted improved survival.
Discussion
We hereby demonstrate that in patients with PAH, TR progression was associated with worsening PH and adverse RV remodelling, characterized by increased RV sphericity, TA dilatation, and TV tethering. The present study also demonstrated a marked plasticity of the RV and tricuspid apparatus, such that a reduction in pulmonary pressures was associated with RV reverse remodelling and reversal of TA dilatation and TV tenting. This led to TR regression and favourable clinical outcome.
Factors associated with TR progression in PAH
Cross-sectional studies have shown an association between PH and TR. 3, 19 All patients in our study had markedly elevated PASP at base-
line, yet not all developed significant TR. Further increase in PASP, increase in RV size, and decrease in TV coverage were independently associated with TR progression. The above triad summarizes the mechanism of TR progression in PAH. Further increase in PASP as a result of pulmonary vascular disease progression led to maladaptive RV remodelling, which led to further TA dilatation and TV tenting, exceeding the ability of the TV leaflets to seal the enlarging TV orifice. This led to TR progression, with superimposed volume-overload-dependent RV remodelling and decreased TV coverage, which rapidly culminated in RV failure and death. In this type of observational study, distinguishing between cause and effect when correlating RV and TV apparatus changes with TR progression is not possible. None of the baseline parameters such as PAH aetiology, PASP, RV size, and TA diameter were useful to predict TR progression, thus limiting our ability to predefine a group of patients at risk for TR progression that may benefit from a more aggressive approach. The results imply that in PAH the rate of disease progression and response to therapy cannot be predicted at baseline. In studies involving patients undergoing surgical or percutaneous mitral valve interventions, baseline PASP did not predict TR progression as well, probably because of the variable response of PASP to interventions. 7 -9 Similarly, in unselected patients referred to echocardiography, PASP change but not baseline PASP predicted TR progression. 5 Taken together, dynamic changes in pulmonary pressures are key determinants of TR progression.
TR progression was associated with a specific RV remodelling pattern, which was most pronounced at the mid-ventricular level with minimal changes in RV length, increasing RV sphericity. RV sphericity has been associated with TR in patients with PH in previous cross-sectional studies. 2, 17 The increase in RV size and sphericity reflect the combined end result of increasing afterload, RV dysfunction, and the volume overload due to TR. Previous studies have shown the importance of TA dilatation and leaflet tethering in the pathogenesis of TR.
17,18,20 -22 Topilsky et al.
concluded that while annular dilatation is the main mechanism of TR due to AF, leaflet tethering is the dominant mechanism in PH. 17 Spinner et al. showed that RV dilatation leads to lateral and apical papillary muscle displacement and leaflet tethering. 23 Using serial echocardiography, we were able to show that in PAH, TR progression is associated with both TA dilatation and leaflet tethering, which together contributes to increased tenting area and TV orifice area, which exceeded TV coverage and decreased coaptation area, leading to worsening TR. The longitudinal design of the present study allowed us to describe for the first time that TR progression is associated with elongation of the TV leaflets. Although the changes were not statistically significant in the TR progression group, the reverse changes in the TR regression group were significant. The tethering forces exerted by the enlarging RV on the TV leaflets may lead to remodelling of the leaflets and increased TV leaflet area. These changes may compensate, in part, for the enlarging tenting area and preserve the coaptation area available to seal the valve. Similar leaflet remodelling has been demonstrated in the mitral valve in patients with functional mitral regurgitation. 24 Importantly, the mechanical stresses imposed by the right-sided papillary muscles in severe PAH may be similar in magnitude to that of functional mitral regurgitation and sufficient to trigger leaflet elongation. In this study, we used the ratio between TV leaflet length and tenting area as an indirect index of leaflet coverage. We found that the changes in TV coverage index indeed correlated with TR progression and regression.
AF, particularly if permanent, has been shown to be an important predictor of TR progression, probably through right atrial and TA dilatation.
5,7 -9,17 AF was uncommon in our PAH patients (11% paroxysmal AF and 1% permanent AF) and had no effect on TR progression. Atrial fibrillation or flutter has been reported to occur in 10 -25% of patients with PAH over 5-6 years and was associated with rapid haemodynamic deterioration if sinus rhythm was not restored. 25 ,26 AF does not play a significant role in TR progression in PAH because it is less frequent than in left heart disease, and because it may rapidly lead to death before TA dilatation.
TR regression in PAH
TR regression was associated with significant reduction in PASP and reverse RV remodelling, reduction in TA diameter and TV tenting, and increased TV coverage despite leaflet shortening. To the best of our knowledge, this is the first report of TR regression in PAH in association with a remarkable RV reverse remodelling. Sadeghi et al. reported TR regression in patients undergoing successful pulmonary endarterectomy, frequently occurring despite persistent TA dilation and no change in valve coaptation. 27 In that study, there was no change in TA diameter or tenting height after surgery, but echocardiography was performed immediately after surgery before reverse RV remodelling occurred. Patients with TR regression were more likely to receive PAH therapy compared with patients with TR progression and invariably demonstrated either a reduction or no change in PASP ( Figure 5) . This group of patients may exhibit a highly favourable response to therapy and is of particular interest for future studies.
TR progression and mortality
Persistent TR progression appears to signal a poor outcome in PAH patients; within 3 years, most patients with TR progression died. TR progression had a lesser effect on survival of patients without PAH and a lesser degree of PH, 5 indicating that the impact of superimposed volume overload is particularly deleterious in PAH. In patients with PAH who were hospitalized for right heart failure, TR severity was an independent predictor of poor outcome. 28 Our study demonstrated a complex and time-dependent relationship between TR severity and mortality, in which the response to pulmonary vasodilators and consequent RV remodelling may play a major role. Because of the remarkable capacity of the RV to undergo reverse remodelling, moderate or severe TR during the first echocardiographic examination does not necessarily imply poor prognosis. However, a progressive increase in TR severity in treated patients is associated with a mortality risk that is exceptionally high.
In the present study, RAP increase, PASP, and RV size at Echo 2, parenteral prostaglandin therapy but not TR progression, independently predicted survival. RAP had been shown to predict survival in several registries and may represent the final common pathway for PH, TR progression, and RV failure, representing the inability of the RV to compensate for the PH. 12 Mean pulmonary artery pressure predicted 5-year mortality in a National Institutes of Health registry of primary PH. 29 In the larger REVEAL registry, pulmonary vascular resistance independently predicted 1-year mortality. 30 This issue is controversial and has not been shown consistently in recent registries. 12 In our study, increasing PASP independently predicted both TR progression and mortality, suggesting that pulmonary vascular disease progression may have had an important effect on patients' outcomes.
Limitations
The study was retrospective and thus limited in its ability to evaluate the effect of PAH therapy on TR progression. TR severity was not assessed using quantitative methods. Quantitative methods for TR estimation have their limitations and are not widely used in clinical practice. 15 Using a semi-quantitative approach, we were able to demonstrate a strong association between TR changes, RV remodelling, and mortality. Our assessment of RV function was limited to the RV fractional area change. However, RV fractional area change is a validated parameter. 16 In patients with very severe TR, especially when there is significant malcoaptation of TV leaflets, the Doppler envelope of the TR jet may be cut off and the simplified Bernoulli equation may underestimate PASP. 16 Malcoaptation of TV leaflets with very severe TR was rare in our patients, probably because PAH patients cannot tolerate very severe TR, and accordingly we do not believe this was a major issue in our study. Invasive haemodynamic measurements were not repeated systematically in synchrony with the echo studies. The RV and TV apparatuses are complex 3D structures, and therefore 3D echocardiography could theoretically have provided additional information. Our cohort consisted of selected prevalent patients, limiting our survival analysis. The facts that all patients had to survive until Echo 2 in order to be included in the study and that dynamic parameters such as change in RAP and TR progression were used to predict survival further limit the applicability of our survival model. Clinical perspective TR should be followed closely in PAH patients and may serve as an endpoint in prospective PAH clinical trials. TR progression despite PAH therapy signals progressive pulmonary vascular disease, RV failure, and poor outcome. These patients should be considered for additional therapeutic options including lung transplantation. TR regression, on the other hand, is a favourable sign and predicts better outcome, but needs to be utilized with other measures of objective improvement.
Conclusions
In PAH, TR progression is associated with progression of pulmonary vascular disease and RV remodelling. RV enlargement and increased RV sphericity lead to TA dilatation and increased TV tethering, which exceeds TV coverage. TR regression is associated with reverse RV remodelling, decreased TA diameter and TV tenting, and improved TV coverage despite leaflet shortening. Stable TR and TR regressions were associated with favourable outcome, whereas TR progression markedly increased the mortality risk. 
